Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review.
BACKGROUND/PURPOSE
Despite its widespread use, no randomised studies have investigated the value of perioperative systemic therapy as adjunct to cytoreduction and HIPEC for colorectal peritoneal metastases. This systematic review evaluated the available evidence, which consists of non-randomised studies only.


METHODS
A systematic search identified studies that investigated the influence of neoadjuvant, adjuvant, or perioperative systemic therapy on overall survival (OS).


RESULTS
The 11 included studies (n=1708) were clinically heterogeneous and subject to selection bias. Studies on neoadjuvant systemic therapy revealed OS benefit (n=3), no OS benefit (n=1), and superiority of chemotherapy with bevacizumab vs. chemotherapy (n=2). Studies on adjuvant systemic therapy showed no OS benefit (n=3). Studies on perioperative systemic therapy demonstrated OS benefit (n=1), and superiority of modern vs. conventional systemic therapy(n=1).


CONCLUSION
Significant limitations of available evidence question the widespread use of perioperative systemic therapy in this setting, stress the need for randomised studies, and impede conclusions regarding optimal timing and regimens. Included studies may suggest a survival benefit of neoadjuvant systemic therapy.
['Rovers|Koen P|KP|', 'Simkens|Geert A|GA|', 'Punt|Cornelis J|CJ|', 'van Dieren|Susan|S|', 'Tanis|Pieter J|PJ|', 'de Hingh|Ignace H|IH|']
D000971:Antineoplastic Combined Chemotherapy Protocols D015179:Colorectal Neoplasms D003131:Combined Modality Therapy D065426:Cytoreduction Surgical Procedures D006801:Humans D020360:Neoadjuvant Therapy D010534:Peritoneal Neoplasms D011379:Prognosis
Peritoneal metastases HIPEC Chemotherapy Colorectal cancer Cytoreductive surgery Peritoneal carcinomatosis Targeted therapy